Alimera Sciences, Inc.
(NASDAQ : ALIM)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Loading ALIM News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-3.48%80.471.8%$677.67m
BIIBBiogen Inc.
-4.02%229.021.0%$525.14m
CELGCelgene Corporation
-4.34%96.291.2%$438.11m
AMGNAmgen Inc.
-3.82%146.451.0%$388.51m
ANACAnacor Pharmaceuticals, Inc.
-0.14%99.0615.2%$320.35m
REGNRegeneron Pharmaceuticals, Inc.
-4.95%339.483.1%$301.85m
ALXNAlexion Pharmaceuticals, Inc.
-8.56%112.992.5%$274.13m
ILMNIllumina, Inc.
-5.24%138.914.9%$155.27m
VRTXVertex Pharmaceuticals Incorporated
-7.14%81.902.6%$124.14m
MDVNMedivation, Inc.
-3.90%56.952.8%$120.74m
BMRNBioMarin Pharmaceutical Inc.
-7.94%77.014.0%$117.35m
SRPTSarepta Therapeutics, Inc.
3.58%18.5249.4%$116.18m
CPXXCelator Pharmaceuticals, Inc.
0.13%30.198.5%$107.30m
AAgilent Technologies, Inc.
-5.48%44.121.0%$94.74m
IONSIonis Pharmaceuticals, Inc.
-6.91%21.978.6%$94.46m

Company Profile

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. It focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its portfolio includes ILUVIEN and NADPH Oxidase Inhibitors. The company was founded on June 4, 2003 by C. Daniel Myers and David R. Holland and is headquartered in Alpharetta, GA.